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Getting to Know Your Board Members
Starting this quarter, the Massachusetts Board of Reg-
istration in Pharmacy will be highlighting a member (or 
two), so that its licensees can get to know more about those 
making decisions for the profession.
This quarter, the Board will highlight its president, 
Michael J. Godek, RPh, and pharmacy technician 
member, Julie Lanza, CPhT.
Michael Godek
Michael “Mike” Godek graduated from Massachusetts 
College of Pharmacy and Health Sciences in 1992, and 
his career with Walgreens began as a staff pharmacist in 
August 1993. As the years progressed, he became a phar-
macy manager, managed two pharmacy departments, and 
was then promoted to district pharmacy supervisor for the 
Boston, MA, area. Walgreens eventually named him area 
health care supervisor, and he was promoted to his current 
role as regional director of operations in June 2015.
As a pharmacy supervisor, he would attend the monthly 
Board meetings and would report on the discussions to 
the Walgreens corporate office. The more meetings he 
attended, the more his desire to be actively involved with 
the Board grew.
Mike was appointed to the Board on November 28, 
2014, and he has found that being involved with the Board 
exceeded his expectations. He finds actively updating regu-
lations to advance the profession of pharmacy and protect 
patient safety very rewarding. 
“I was both humbled and honored to be elected as the 
Board of Pharmacy president for 2018,” he said. As presi-
dent, preparation for the monthly meetings takes a little 
longer, but creativity with time management is essential. 
The Board president must facilitate the meeting and the 
conversations around the issues being discussed. If con-
versations get off-topic, it is the Board president’s job to 
redirect the conversation.
Board members come from many different backgrounds 
and practice settings, and everyone’s participation is impor-
tant and valuable. It is okay to have differences of opinion 
as long as the goal of patient safety remains priority.
Mike feels that some of the biggest challenges fac-
ing Board members are keeping regulations and polices 
congruent with the evolution of the profession and with 
society. The current opioid crisis, not only in the state of 
Massachusetts but in the entire nation, is a prime example.
“If I look back on my career, I think I would give the 
advice to always have the best interest of the patient in 
mind; if you are not sure about a policy, do not hesitate to 
ask; be truthful and respectful because we are all human, 
and humans make mistakes,” Mike said. “It all depends 
on how you handle yourself, and you will learn something 
along the way. In short, never compromise your integrity 
or work ethic.”
Julie Lanza
As one of the 13 members of the Board, Julie Lanza 
occupies the pharmacy technician seat as designated and 
required by law. She has been a certified pharmacy techni-
cian at Beth Israel Hospital for 19 years and has been in 
her current regulatory role for the last 18 months. Julie is 
committed to pharmacy as indicated by her involvement 
in organizations such as the American Society of Health-
System Pharmacists and Massachusetts Society of  Health-
System Pharmacists.
Having been appointed to the Board in December 2017, 
Julie said she is both “overwhelm[ed] and excit[ed]” to be a 
part of  the team. Being the only pharmacy technician on the 
Board, Julie felt a little uncomfortable on her first day, but 
quickly felt at ease after meeting the other Board members 
and staff. “As soon as I sat down and met everyone, the 
pressure went away,” she said.
Her role with the Board began with her desire to take on a 
new path. She explained that she “thought it would provide 
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♦ respond to stakeholder feedback requesting guid-
ance on the meaning of “facility” under section
503B.
In the guidance, FDA explains that a section 503A 
establishment compounding drugs pursuant to pa-
tient-specific prescriptions may be located near or in 
the same building as the outsourcing facility provided 
that they are completely separate. As explained in the 
guidance, the boundaries between the section 503A 
establishment and outsourcing facility should be clear 
and may include permanent physical barriers, such as 
walls or locked doors, and the two operations should 
not share rooms, equipment, supplies, or pass-through 
openings (eg, they may not subdivide a room with 
temporary barriers such as curtains). The guidance 
further explains that the labeling should clearly iden-
tify the compounder who produced the drug. Lastly, 
the guidance reminds industry and stakeholders that 
all drug products compounded in an outsourcing facil-
ity are regulated under section 503B and are subject 
to current good manufacturing practice requirements, 
even if those drug products are compounded pursuant 
to patient-specific prescriptions. Additional infor-
mation can be located at www.fda.gov/newsevents/
newsroom/fdainbrief/ucm607339.htm.
EU-US Mutual Recognition Agreement 
Now Operational Between FDA and 12 
Member States 
In January 2018, FDA confirmed the capability 
of four more European Union (EU) member states – 
Czech Republic, Greece, Hungary, and Romania – to 
carry out good manufacturing practice inspections at 
a level equivalent to the United States. With the addi-
tion of the four EU member states, FDA can now rely 
on inspection results from 12 EU member states. The 
mutual recognition agreement between the EU and US 
to recognize inspections of manufacturing sites for hu-
man medicines conducted in their respective territories 
is progressing as planned, with plans for the agreement 
to be operational in all EU member states by July 15, 
2019, indicates a European Medicines Agency (EMA) 
press release. In 2017, FDA determined the agency will 
recognize eight European drug regulatory authorities in 
Austria, Croatia, France, Italy, Malta, Spain, Sweden, 
and the United Kingdom as capable of conducting 
Page 2
SAMHSA Publishes Guidance for 
Treating OUD
To help broaden health care professionals’ un-
derstanding of medications that can be used to treat 
Americans with opioid use disorder (OUD), the 
Substance Abuse and Mental Health Services Ad-
ministration (SAMHSA) offers guidance on clinical 
best practices in the February 2018 publication titled 
Treatment Improvement Protocol 63, Medications for 
Opioid Use Disorder. The publication reviews the use 
of the three Food and Drug Administration (FDA)-
approved medications used to treat OUD – metha-
done, naltrexone, and buprenorphine – and other 
strategies and services needed to support recovery 
for people with OUD. 
Additionally, in February 2018, SAMHSA released 
the publication Clinical Guidance for Treating Preg-
nant and Parenting Women with Opioid Use Disorder 
and Their Infants, which offers standard approaches 
for health care professionals. This publication pro-
vides evidence-based treatment options, including 
pharmacotherapy with methadone, buprenorphine, 
and buprenorphine/naloxone, for pregnant women 
with OUD. The clinical guidance also helps health 
care professionals and patients determine the most 
clinically appropriate action for a particular situation 
and informs individualized treatment decisions. Both 
publications can be found in the Publications section 
of SAMHSA’s website at www.samhsa.gov.
FDA Issues Final Guidance Policy on 
Outsourcing Facilities 
In May 2018, FDA issued a new policy designed 
to address any ambiguity around how to define the 
physical features and operations of outsourcing facili-
ties. According to FDA Commissioner Scott Gottlieb, 
MD, the policy in the final guidance, Facility Defini-
tion Under Section 503B of the Federal Food, Drug, 
and Cosmetic Act, will help to:
♦ ensure that compounded drugs are made under
appropriate quality standards;
♦ provide transparency to patients and health care
providers about the standards under which the
compounded drugs that they purchase are made;
and
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inspections of manufacturing facilities that meet FDA 
requirements. The EMA news release, “Four more EU 
Member States benefit from EU-US mutual recognition 
agreement for inspections,” can be found in the News 
and Events section at www.ema.europa.eu.
US Surgeon General Advisory Urges 
More Individuals to Carry Naloxone
In an April 2018 advisory, US Surgeon General Jerome 
M. Adams, MD, MPH, emphasizes the importance of
more individuals knowing how to use naloxone and keep-
ing it within reach. Surgeon General Adams recommends
that family, friends, and those who are personally at risk
for an opioid overdose keep the drug on hand. As stated
in the advisory, expanding the awareness and availability
of naloxone is a key part of the public health response
to the opioid epidemic. The Surgeon General advisory
on naloxone is part of the Trump Administration’s ongo-
ing effort to respond to the sharp increase among drug
overdose deaths, notes a US Department of Health and
Human Services (HHS) news release. HHS also has a
website, www.hhs.gov/opioids, with resources and in-
formation for individuals who want to fight the opioid
crisis in their communities or find help for someone in
need. The advisory and news release can be found at
www.surgeongeneral.gov.
Expanding Pharmacists’ Scope 
of Practice Linked to Improved 
Cardiovascular Outcomes 
Elevating pharmacy involvement in patient care and 
using a team-based care model are among the effective 
strategies for preventing cardiovascular disease that 
were identified in a new guide developed by the Centers 
for Disease Control and Prevention’s (CDC’s) Division 
for Heart Disease and Stroke Prevention (DHDSP). 
The guide, Best Practices for Cardiovascular Disease 
Prevention Programs: A Guide to Effective Health 
Care System Interventions and Community Programs 
Linked to Clinical Services, describes the scientific 
evidence behind each strategy, including collaborative 
drug therapy management, enabled by a collaborative 
practice agreement, and medication therapy manage-
ment. To be included in the guide, strategies had to be 
supported by multiple high-quality research studies 
that demonstrated evidence of effectiveness in control-
ling blood pressure or cholesterol levels. More details 
about the best practice strategies along with resources 
and tools for implementing the strategies identified by 
CDC’s DHDSP can be found at www.cdc.gov/dhdsp/
pubs/guides/best-practices/index.htm.
Pharmacists Are Critical to Drug 
Supply Chain Integrity, States FIP 
Medicines are specialized commodities and, if they 
are not managed rationally or appropriately, they are 
equivalent to a dangerous substance, indicates the 
International Pharmaceutical Federation (FIP). In a 
May 2018 report, Pharmacists in the supply chain: 
The role of the medicines expert in ensuring quality 
and availability, FIP provides a global picture of the 
role of pharmacists in supply chains, the tasks cur-
rently undertaken by pharmacists in different coun-
tries, and pharmacists’ unique competencies. Based 
on reviews of literature, survey data, and case studies 
from nine countries, pharmacists were identified as 
having expertise that is critical to supply chain integ-
rity. According to FIP, pharmacists and those who are 
involved in the planning, procurement, manufacture, 
storage, and distribution of medicines must:
♦ consider how to most effectively use the skills of
the staff and personnel available;
♦ provide and seek training where needed; and
♦ keep their systems and role descriptions under re-
view in order to adapt to changing circumstances.
FIP’s report and news release can be located at 
www.fip.org/news_publications. 
Emergency Department Visits for 
Opioid Overdoses Rose 30%
From July 2016 through September 2017, reports 
of emergency department (ED) visits for opioid 
overdoses – including prescription pain medications, 
heroin, and illicitly manufactured fentanyl – rose 30% 
in all parts of the US, according to a CDC report. The 
Midwest saw opioid overdoses increase 70% during 
this time period. According to the March 9, 2018 
Morbidity and Mortality Weekly Report, coordinated 
action between EDs, health departments, mental 
health and treatment providers, community-based 
organizations, and law enforcement can prevent 
opioid overdose and death. People who have had an 
overdose are more likely to have another; thus, be-
ing seen in the ED is an opportunity for action. EDs 
can provide naloxone, link patients to treatment and 
referral services, and provide health departments with 
critical data on overdoses. The CDC report, “Vital 
Signs: Trends in Emergency Department Visits for 
Suspected Opioid Overdoses — United States, July 
2016–September 2017,” can be accessed at http://
dx.doi.org/10.15585/mmwr.mm6709e1.
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[an opportunity] to be an advocate for technicians.” Julie 
hopes to add value to the Board by providing a different 
outlook, stating, “I feel that I can offer a perspective that the 
other members cannot. That’s what I meant by advocating. 
I can look through the lens of a technician.”
One of the biggest obstacles Julie faced in her duties 
as a Board member was to become more knowledgeable 
about other areas of the profession where she does not 
have as much experience. To enhance her participation in 
these areas, Julie said she desired to “overcom[e] the lack 
of experience with other practice settings . . . [and] learn 
about other practice settings to be able to make a good 
decision when voting on matters involving others.”
When asked if she had any words of advice to give to 
other pharmacy technicians in Massachusetts, Julie stated, 
“That’s easy. I would tell them that the role of pharmacy 
technicians is changing, and they should never pass up 
any opportunities that come with the change. Whether it is 
making presentations, attending meetings, or sitting on the 
Board, never pass up an opportunity to advance and show 
the world what the value of technicians can be. Advocacy 
really needs to come from within.”
Delivery Best Practices Overview
The Board has developed a Best Practice Recommen-
dations for Prescription Delivery document. In addition 
to general recommendations, this guidance document 
advises on obtaining patient consent for delivery and 
provides specific recommendations for federally desig-
nated controlled substances (CS), hazardous drugs, and 
temperature-sensitive products. 
Among other things, appropriate shipping containers 
and tamper-resistant tape should be utilized. For federally 
designated CS, consider having two employees verify the 
contents before sealing the package. Consider removing 
the name of  the pharmacy and any other pharmacy indica-
tors from the package to deter tampering or theft during 
transport.
Track lost packages through the courier and notify the 
proper authorities, if necessary. If  the lost package contains 
federally designated CS or drugs with abuse potential, re-
port it to Drug Enforcement Administration (DEA) and the 
Board in accordance with DEA’s policy on requirements 
and procedures for reporting theft or loss of CS.
When delivering temperature-sensitive medications, 
have policies and procedures requiring time-test studies 
at least twice yearly to ensure products maintain their 
temperature throughout the delivery process. Review 
the National Institute for Occupational Safety and Health 
list and package hazardous products separately whenever 
delivering or shipping. If a specialty pharmacy delivers to 
another pharmacy location for patient pickup, it must be 
in its final packaging, as the receiving pharmacy may not 
alter the package in any way.
Counseling for delivered medications may be in the form 
of  written drug information containing a phone number to 
call the pharmacy for questions. Include a proper measuring 
device with all liquid medications. In the event the package 
is returned to the pharmacy as undeliverable, notify the 
patient and document the receipt of the returned package. 
Conduct background checks for contracted drivers, 
provide and document annual training, and have a policy 
in place to ensure that deliveries to an assisted living facil-
ity are not left at the front desk or in the hands of a staff 
member. Deliveries should be documented and logs with 
recipient signatures retained. 
This best practices document contains many more recom-
mendations. Please review the full document here. 
Vaccinations
Now that it is flu season, the Board suggests a refresher 
of its policy on vaccinations. Protect yourself and your 
patients by encouraging flu shots for all. 
Did You Know?
♦ To view policies, regulations, and other helpful informa-
tion online, visit the “What you need to know” web page
on the Board’s website.
♦ The easiest and fastest way to renew your pharmacist’s
license is online. Avoid any technical issues, penalties,
or late fees by doing it as soon as possible!
♦ Effective December 31, 2018, any retail stores containing
Board-licensed pharmacies may no longer sell tobacco
products, per Chapter 157 of the Acts of  2018, which
was passed in July 2018.
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